An update on osteoporosis

American Journal of Therapeutics

Volumn 16, Issue 5, 2009, Pages 437-445

  Nochowitz, Beth ^a   Siegert, Sherry ^b   Wasik, Mitzi ^b,c  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Black Witch University and Chicago Women's Health Center   (United States)

Author keywords

Bisphosphonates; Calcitonin; Calcium; Estrogen replacement therapy; Hormone replacement therapy; Osteopenia; Osteoporosis; Selective estrogen receptor modulators; Teriparatide

Indexed keywords

ALENDRONIC ACID; ANTICOAGULANT AGENT; BARBITURIC ACID DERIVATIVE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; BUMETANIDE; CALCITONIN; CALCIUM; CATHEPSIN K INHIBITOR; COLECALCIFEROL; ESTROGEN; ETIDRONIC ACID; FUROSEMIDE; GLUCOCORTICOID; IBANDRONIC ACID; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; ONO 5334; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TORASEMIDE; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

BODY MASS; BONE REMODELING; BREAST CANCER; CALCIUM INTAKE; CAUSE OF DEATH; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DAILY LIFE ACTIVITY; DRUG COST; DRUG MECHANISM; DRUG MONITORING; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; EXERCISE; FEVER; FLU LIKE SYNDROME; FRAGILITY FRACTURE; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HEADACHE; HEALTH INSURANCE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; JAW OSTEONECROSIS; MORBIDITY; MORTALITY; MYALGIA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PAIN; PATHOGENESIS; PATIENT COMPLIANCE; PATIENT COUNSELING; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; RISK FACTOR; SMOKING CESSATION; SPINAL CORD COMPRESSION; SPINE FRACTURE; STROKE; UNITED STATES; VEIN THROMBOSIS; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; WEIGHT BEARING; WEIGHT REDUCTION;

AGE FACTORS; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; RISK FACTORS; UNITED STATES;

EID: 70349690610     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31818637de     Document Type: Review

References (46)

1. National Osteoporosis Foundation. Clinicians Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
2. Singer A. Osteoporosis diagnosis and screening. Clin Cornerstone. 2006;8(1):9-18.
3. South-Paul JE. Osteoporosis: part I. Evaluation and assessment. Am Fam Physician. 2001;63:897-904.
4. Gennari L, Bilezikian J. Osteoporosis in men. Endocrinol Metab Clin North Am. 2007;36:399-419.
5. U.S. Preventive Services Task Force. Screening for Osteoporosis, Topic Page. Rockville, MD: Agency for Healthcare Research and Quality; 2002. Available at: http://www.ahrq.gov/clinic/uspstf/uspsoste.htm. Accessed June 28, 2008.
6. Osteoporosis. ACOG Practice Bulletin No.
7. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2004;103:203-216.
8. World Health Organization. Assessment of osteoporosis at the primary health care level. Summary Report of a WHO Scientific Group. WHO, Geneva. www.who/int/ chp/topics/rheumatic/en/index.html. Accessed June 18, 2008.
9. Sirius ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108-1112.
10. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
11. FRAX WHO fracture risk assessment tool. Sheffield (UK): World Health Organization Collaborating Centre for Metabolic Bone Diseases. University of Sheffield; 2008. Available at: http://www.shef.ac.uk/FRAX/index.htm. Accessed June 18, 2008.
12. Low bone mass (osteopenia) and fracture risk. ACOG Committee Opinion No.407. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2008; 111:1259-1261.
13. Dontas I, Yiannakopoulos C. Risk factors and prevention of osteoporosis-related fractures. J Musculoskelet Neuronal Interact. 2007;7:268-272.
14. American Association of Clinical Endocrinologists. AACE Osteoporosis Guidelines. Endocr Pract. 2003;9:544-564.
15. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29:441-464.
16. Optimal Calcium Intake. NIH Consensus Statement 1994 June 6-8. 1994;12(4):1-31.
17. Fosamax [package insert]. Whitehouse Station, NJ: Merck & Co; 2007.
18. Actonel [package insert]. Cincinnati, OH: Proctor & Gamble; 2007.
19. Boniva [package insert] Research Triangle Park, NC: Roche; 2006.
20. Reclast [package insert]. East Hanover, NJ: Novartis; 2007.
21. Black D, Cummings S, Karpf D, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
22. Cummings S, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA. 1998;280:2077-2082.
23. Adami S. Bisphosphonate antifracture efficacy. Bone. 2007;41(5):S8-S15.
24. Chesnut CH, Skag A, Christiansen C, et al. Daily vs. intermittent oral ibandronate. J Bone Miner Res. 2004;19: 1241-1249.
25. Harris S, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999;282:1344-1352.
26. McClung M, Geusens P, Miller PD, et al. The effect of risedronate on the risk of hip fracture in elderly women: hip intervention program study group. N Engl J Med. 2001;344: 333-340.
27. Black DM, Delmas PD, Eastell R, et al. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
28. Evista [package insert]. Indianapolis, IN: Eli Lilly and Company; 2007.
29. Women's Health Initiative Investigators. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy, the women's health initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
30. Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women, principal results from the women's health initiative randomized controlled trial. JAMA. 2002; 288:321-333.
31. Miacalcin [package insert]. East Hanover, NJ: Novartis; 2006.
32. Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2007.
33. Zometa [package insert]. East Hanover, NJ: Novartis; 2008.
34. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
35. Murray L. 2007 Red Book. Montvale, NJ: Thomson Healthcare Inc; 2007.
36. Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors and clinical characteristics. Clin Ther. 2007;29:1548-1558.
37. Gutta R, Louse PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:186-193.
38. Bilezikian JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med. 2006;355:2278-2281.
39. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356:1895-1896.
40. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168:826-831.
41. Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008:336:813-816.
42. Denosumab. Available at http://www.amgen.com/ science/pipe-denosumab. html. Accessed June 18, 2008.
43. Wyeth. Wyeth Receives Approvable Letter From FDA for Bazedoxifene For the Treatment of Postmenopausal Osteoporosis. Available at http://www.wyeth.com/ news?nav=display&navTo=/wyeth-html/home/news/ pressreleases/ 2008/1211544306664.html. Accessed June 18, 2008.
44. Riis B. A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D. Available at http:// clinicaltrials.gov/ct2/show/NCT00525798?term=osteoporosis& recr=Open&rank=15. Accessed June 18, 2008.
45. A Study of MK0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk Reduction. Available at http://clinicaltrials.gov/ct2/show/ NCT00529373?term=osteoporosis&recr=Open&age= 12&phase=23&fund= 2&rank=13. Accessed June 18, 2008.
46. Kuwayama T. Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis. http://clinicaltrials.gov/ct2/show/NCT00532337?term= osteoporosis&recr=Open&age=12&fund=2&rank=6. Accessed June 18, 2008.